Gerald Dryden, MD
Gastroenterology · Louisville, KYNPI 1619969011
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,792,490 of the $2,126,914 with a category attached, or 84.3%. 23 manufacturers reported payments, led by AbbVie at 28.4% of the total. Among gastroenterology clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,368 payments — averaging $1554.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$605K
- Takeda Pharmaceuticals U.S.A., Inc.$442K
- Janssen Scientific Affairs, LLC$338K
- Johnson & Johnson$336K
- Lilly USA, LLC$188K
- Phathom Pharmaceuticals, Inc.$129K
- plus $90K from 17 others
Across 435 payments — averaging $3167.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$604K
- Janssen Research & Development, LLC$369K
- Takeda Pharmaceuticals U.S.A., Inc.$96K
- Gilead$78K
- Teva Pharmaceuticals USA, Inc.$62K
- E.r. Squibb & Sons, L.L.C.$48K
- plus $120K from 5 others
What the payments were for
- Consulting fees$106,0105%
- Speaking & faculty fees$1,792,49084%
- Travel & lodging$193,9829%
- Food & beverage$34,2522%
- Education$1790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 452 | $604,843 |
| Takeda Pharmaceuticals U.S.A., Inc. | 213 | $441,620 |
| Janssen Scientific Affairs, LLC | 205 | $337,603 |
| Johnson & Johnson | 208 | $335,550 |
| Lilly USA, LLC | 117 | $187,953 |
| Phathom Pharmaceuticals, Inc. | 87 | $129,401 |
| Pfizer | 45 | $63,853 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $14,983 |
| Bristol Myers Squibb | 1 | $3,080 |
| Gilead | 3 | $2,918 |
| Janssen Global Services, LLC | 1 | $2,505 |
| Genentech USA, Inc. | 4 | $1,837 |
| Steris Corporation | 1 | $158 |
| Biogen | 1 | $150 |
| E.r. Squibb & Sons, L.L.C. | 1 | $122 |
| Lumendi LLC | 1 | $85 |
| Ardelyx, Inc. | 4 | $74 |
| Boston Scientific | 1 | $71 |
| Celltrion USA Inc. | 2 | $35 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| Conmed Corporation | 1 | $18 |
| Merck | 1 | $17 |
| GE HealthCare | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,126,914 in reported general payments places this provider in the 95th percentile of 207 gastroenterology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 46 | $1,241,517 |
| RinvoqUpadacitinib | 60 | $393,887 |
| Humira(Cf) PenAdalimumab | 12 | $88,550 |
| LinzessLinaclotide | 19 | $19,945 |
| VoqueznaVonoprazan Fumarate | 29 | $18,407 |
| Mesalamine | 32 | $16,762 |
| Azathioprine | 27 | $865 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 20 | $590 |
| Dicyclomine Hcl | 22 | $562 |
| Pantoprazole Sodium | 32 | $540 |
| Esomeprazole Magnesium | 13 | $388 |
| Promethazine Hcl | 34 | $259 |
| Omeprazole | 44 | $250 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $335,550 | $1,241,51746 claims |
| AbbVieRinvoq, Linzess | $604,843 | $413,83279 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $129,401 | $18,40729 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 207 gastroenterology providers in Kentucky.
Other gastroenterology in Louisville
- Matthew CaveLouisville$340K
- Michael KreaseLouisville$322K
- Sunana SohiLouisville$220K
- Jeffrey TuvlinLouisville$202K
- Stephen McClaveLouisville$124K
- Ashutosh BarveLouisville$43K
- Thomas AbellLouisville$36K
- Nanlong LiuLouisville$31K
- Craig McClainLouisville$22K
- John HorlanderLouisville$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.